clinical trial · NCT07204457
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Meningococcal InfectionsEG-MCV4Menveo
brief summary
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
started
Oct 15, 2025
primary completion
Sep 1, 2026
completion
Jun 1, 2027
last updated
Dec 1, 2025
official title
Multicenter, Randomized, Subject/Evaluator Blind, Active Control, Phase II/III Clinical Trial to Assess Immunogenicity and Safety of EG-MCV4 Meningococcal (Groups A, C, W-135, and Y) Conjugated Vaccines
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol